(Date:11/30/2009)... , NOVATO, Calif., Nov. 30 /PRNewswire-FirstC...N ) announced today that the Food and Drug Adminis...for 3,4-diaminopyridine (3,4-DAP), amifampridine p...Eaton Myasthenic Syndrome (LEMS). 3,4-DAP has pre...U. Also, in October 2009, the Committee for Medic...
(Date:11/30/2009)... , BOSTON and COPENHAGEN, Nov. 30 /PRNewsw...announced today that the Harvard Medical School IC...ecognized as a MicroRNA Screening Center of Excell...dical School, and associated hospitals and institu...cule and RNAi libraries. ,, MicroRNAs are a nov...
(Date:11/30/2009)... , AMSTERDAM, N... world,s,leading publisher of scientific, medical ...ed a major re-launch of Embase, its comprehensive ...dexed records from more than 7,000,active, peer re... a key role in the advancement of new biomedical,a...
(Date:11/27/2009)... , DURHAM, N.C., Nov. 27 /PRNewswire/ ... will initiate water-soluble carbon nanotube-based...The water-soluble carbon nanotubes, which have fun...ation with cancer drugs, was developed in partners... conjugated carbon nanotubes serves as a drug deli...
Breaking Biology Technology:FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 2Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 3Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 2Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 3North Carolina Based Cromoz Inc. Launches Carbon Nanotechnology for Target Drug Delivery System in Cancer Treatment in Hyderabad, India 2(Date:12/1/2009)...FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a b...tary antibodies for the treatment of cancer, infla...at Bayer Schering Pharma AG has exercised its opti...eement entered into on January 12, 2009 to develop...mors. ,, Under the terms of the agreement, Baye...
(Date:11/30/2009)...ewswire/ -- Microban International, Ltd., the glob...tion, is pleased to announce their exclusive North...est U.S. manufacturer and distributor of ceramic t... two new lines of ceramic tile with OutStand Techn...g silver based technology, in order to create a li...
(Date:11/30/2009)...Newswire-FirstCall/ -- Nektar Therapeutics (Nasdaq...e Masuoka, M.D. to Senior Vice President and Chief...y to Nektar,s President and Chief Executive Office...g leadership and highly effective clinical develop...advancing Nektar,s proprietary clinical pipeline, ...
Breaking Medicine Technology:Bayer Schering Exercises Option to Develop Solid Tumor BiTE Antibody with Micromet 2Bayer Schering Exercises Option to Develop Solid Tumor BiTE Antibody with Micromet 3Bayer Schering Exercises Option to Develop Solid Tumor BiTE Antibody with Micromet 4Dal-Tile Corp. Launches Two New Lines of Ceramic Tile with Microban(R) Silver Antimicrobial Technology 2Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer 2Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer 3Midlife Heart Risk Factors Linked to Later Dementia 53613 1Midlife Heart Risk Factors Linked to Later Dementia 53613 2Midlife Heart Risk Factors Linked to Later Dementia 53613 3CVS Caremark and Inverness Medical Innovations Launch Strategic Alliance to Provide Enhanced Health Management Services to Clients 53611 1CVS Caremark and Inverness Medical Innovations Launch Strategic Alliance to Provide Enhanced Health Management Services to Clients 53611 2CVS Caremark and Inverness Medical Innovations Launch Strategic Alliance to Provide Enhanced Health Management Services to Clients 53611 3CVS Caremark and Inverness Medical Innovations Launch Strategic Alliance to Provide Enhanced Health Management Services to Clients 53611 4More Than One in Five 12 to 17 Year Olds Have Trouble Seeing in Class 53609 1More Than One in Five 12 to 17 Year Olds Have Trouble Seeing in Class 53609 2More Than One in Five 12 to 17 Year Olds Have Trouble Seeing in Class 53609 3More Than One in Five 12 to 17 Year Olds Have Trouble Seeing in Class 53609 4